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The 3-nitrosobenzamide (NOBA) drug abolishes SIV replication sharply at 20 ,uM concentration when CEM x174 cells are preincubated for 1 h 
with the drug prior to viral infection. Treatment of CEM x174 cells with 20 ¢tM NOBA resulted in the inhibition of the synthesis of the DNA 
sequence coding for the gag gene, as determined by the PCR technique. Cell viability was directly proportional to the antiviral action of NOBA. 
Replication of AZT-resistant SIV 23740 in MMU 23740 cells in vitro was suppressed by NOBA in a concentration-dependent ma ner without 
significant effects on cell viability. Reverse transcriptase activity of SIVm~,c239 was unaffected by NOBA up to 800,uM concentration. Preincubation 
of two SIV strains with NOBA completely abolished their infectivity in human PHA-PBL cells. Replication of two strains of SIV in PHA-PBL 
cells was also inhibited by NOBA. 
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1. INTRODUCTION 
Animal models are essential in evaluating antiviral 
agents for chemotherapy [1]. In the case of the acquired 
immunodeficiency s ndrome (AIDS), the first drug es- 
tablished to be active but not curative was AZT [1-3]. 
A decrease in HIV core antigen levels and virus titer in 
the plasma of patients treated with AZT has been re- 
ported [4]. Since prolonged treatment with AZT leads 
to the emergence of drug-resistant s rains of HIV [5], 
novel agents for AIDS chemotherapy appear to be nec- 
essary. 
We have reported that two aromatic C-nitroso com- 
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immunodeficiency virus; MMU, Macaca mulatta; MTT, 3-(4,5-di- 
methylthiazol-2-yl)-2,5-diphenyltetrazolium br mide; NOBA, 3-ni- 
trosobenzamide; NOBP, 6-nitroso-l,2-benzopyrone; PBMCs, periph- 
eral blood mononuclear cells; PCR, polymerase chain reaction; PHA- 
PBL, phytohaemagglutinin-stimulated human peripheral blood lym- 
phocytes; RT, reverse transcriptase; SIV, simian immunodeficiency 
virus; SIVsm m and SIVmrnb i are SIV strains; TCIDs0, 50% tissue culture 
infectious dosage. 
pounds, 6-nitroso-l,2-benzopyrone (NOBP) and 3-ni- 
trosobenzamide (NOBA), induce zinc ejection from iso- 
lated zinc fingers of p7 or from HIV-1 virions and in- 
hibit HIV-1 replication in human lymphocytes [6]. Since 
NOBA was more effective in suppressing HIV-1 propa- 
gation than NOBP and was well tolerated by uninfected 
lymphocytes [6], this drug appeared to be the agent of 
choice for further studies. 
SIV in terms of genetics and CD4 cell tropism is by 
far the closest animal retrovirus to HIV [7]. Further- 
more, SIV and HIV contain similar MgZ+-dependent 
reverse transcriptases [8] and their major core proteins 
reveal common antigenic regions [9]. Thus SIV infection 
of rhesus macaques, which leads to an immunodefi- 
ciency syndrome similar to that found in HIV-infected 
humans, remains the best animal model available for 
the study of the pathogenesis of AIDS [10]. Since pre- 
clinical testing of new antiviral agents in animal models 
is generally preceded by cell culture studies [11], we 
determined the effect of NOBA on SIV replication in 
CEM x 174 cells in vitro and compared these results 
with the effect of NOBA on AZT-resistant SIV 23740. 
We also tested the hypothesis that each of the two drugs 
(AZT, NOBA) should exert specific independent modes 
of action on SIV replication and therefore AZT-resis- 
tant viral strains should still respond to the antiviral 
action of NOBA. For comparison with earlier studies 
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Fig. 1. The effect of NOBA on SIVm,c239 replication (A) and CEM x174 cell viability (B). Details of experimental protocol are described in the 
text (section 3). Each bar expresses the mean of 3 independent tests, which do not differ _+ 10% (not shown). In A, ordinate = p27 antigen assay 
(ELISA) performed on day 10; abscissa = concentration of NOBA or DMSO. In B, cell viability test determined on day 10 by the tetrazolium assay 
(see section 2); first line bars = virus infected cells (SIV) in the presence of NOBA; second line bars (controls) = uninfected cells treated with NOBA. 
[6] we also determined the effect of NOBA on SIV rep- 
lication in human lymphocytes. 
2. MATERIALS AND METHODS 
CEM x174 cells are the fusion product of human B cell line 721.174 
and human T cell line CEM [12]. A molecular clone of SlY ..... 
(SIVm,c239) was kindly provided by Dr. R. Desrosiers of the New 
England Primate Research Center. AZT (3'-azido-2',3'-dideoxythy- 
midine) was manufactured by the Burroughs Wellcome Co. The com- 
pound 3-nitrosobenzamide (NOBA) was prepared by Octanaer Inc., 
Tiburon, CA*. RPMI 1640 supplemented with n-glutamine was pur- 
chased from Gibco Labs. Inc. 
2.1. Preincubation with the drug 
CEM x174 cells were suspended at 4 x 105 cells/ml and distributed 
into 24-well tissue culture plates. Cultures were treated with various 
concentrations of the test compound (along with DMSO as controls) 
and incubated at 37°C for 1 h in a CO2incubator. The cells were 
infected with 5/11 of a stock solution of SIVm,c239 at 300 TCIDs0/ml 
(50% tissue culture infectious dosage per ml cell suspension). Cell 
viability was determined by the tetrazolium salt (MTT) assay and the 
cultures were divided 1:4 every 34  days in medium containing the 
drug. The cultures were examined periodically by light microscopy for 
the presence of syncytia, The virus titers were determined by analysis 
of supernatant SIV p27 core antigen protein or reverse transcriptase 
(RT) levels. 
2.2. Preincubation with the virus 
CEM x174 cells were distributed into 24-well tissue culture plates 
as above. Cells were incubated with virus for 2 days (until syncytia 
appeared) before treatment with NOBA. Cultures were examined pe- 
riodically for the presence of syncytia. Virus titers were determined by 
SIV p27 or RT assays. 
2.3. RT assays 
To test for RT activity, 10/A of infected cell supernatant was added 
to a reaction mixture containing 50 mM Tris-HCl (pH 8.0), 5 mM 
MgC12, 10 mM dithiothreitol (DTT), 20 mM KCI, and 1% Triton 
X-100 in a total volume of 50 yl. Poly(rA).oligo(dT)~2 is was present 
at 100 ,ug/ml and [~H]TTP at 2.4 ,uM. The reaction mixtures were 
incubated at 37°C for 1 h and the TCA-precipitable radioactivity was 
filtered onto nitrocellulose filters which were then washed, dried, and 
counted. 
2.4. Tetrazolium salt (MTT) assays 
Cell viability was measured by a published procedure [13]. Briefly, 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium br mide) 
was dissolved at a concentration of 5 mg/ml in sterile phosphate 
buffered saline (PBS). 20/tl of MTT solution were added into each 
microtiter well containing t 00/B of cell culture. Following 2 h incuba- 
tion at 37°C, 100/11 of solubilizing medium (cf. [13]) were added. After 
overnight incubation at 37°C, optical densities were measured at 570 
nm using a microtiter plate reader. 
2.5. SIV,,,,~ p27 core antigen levels" 
These were determined by an enzyme immunoassay provided by 
Coulter Corp. (Hialeah, FL). The assay was performed according to 
the manufacturer's specifications. 
2.6. Polymerase chain reaction ( PCR) analysis of infected cell genomes 
DNA extracted from drug-treated, SIV-infected CEM x174 cells or 
from control cells were screened for the presence of the SIV sequence 
by a published method [14] using individually designed primers corre- 
sponding to the SIV gag gene. Northern hybridization has shown the 
primers to be complementary to the region encoding the major core 
antigen protein, p27 [14]. 
2.7. Assays on human lymphoeytes 
These were performed as described previously [6]. 
*Kun, E., Mendeleyev, J. Rice, W.G., US Patent, Ser. No. 07/780,809, 
pending. 
3. RESULTS 
The effectiveness of NOBA in preventing SIVm.c239 
replication in CEM x174 cells was determined by prein- 
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A 
cubating cells with varying concentrations of NOBA at 
37°C for 1 h before infection with the virus. As illus- 
trated in Fig. 1A, pretreatment of CEM x174 cells with 
0 to 20/.tM NOBA and maintenance of these drug con- 
centrations during the entire experimental period strik- 
ingly abolished SIVm,c239 replication only at 20/ IM 
NOBA; no effect of NOBA was detected at lower drug 
concentrations. The exact reasons for the sharp transi- 
tion between ineffective (below 15 ~tM) and fully effec- 
tive (20 pM) NOBA concentrations are not known, but 
we presume that the quantity of intracellular NOBA- 
inactivating systems may explain this phenomenon, 
which is overcome by higher than 15/IM NOBA. Coin- 
cidental with the antiviral action of 20 pM NOBA cell 
viability was maintained at the level of virus-free con- 
trols (Fig. 1B), however, when SIV p27 levels were high 
the cytocidal action of SIVmac239 was reflected in a 
significantly depressed cell viability, as would be pre- 
dicted. 
Since virus replication was expected to coincide with 
the appearance of integrated viral DNA in the genome 
of CEM x174 cells, we assayed cellular DNA by the 
PCR method (see section 2) with the aid of specifically 
designed gag-selective SIV primers [14]. Results of the 
PCR assay are shown in Fig. 2. Lane 1 in Fig. 2A is a 
molecular marker (HindIII-digested ¢X174 DNA), and 
lane 2 is the plasmid DNA encoding the SIV p27 core 
antigen protein amplified by gag-specific primers. Lane 
3 illustrates the absence of the specific amplified DNA 
from non-infected control cells, and lanes 4-7 show the 
result of PCR assay in SIV-infected cells in the absence 
of NOBA (lane 4), with 0.1% DMSO (lane 5) and after 
preincubation and treatment with 10 tiM NOBA (lane 
6) and finally with 20 ,uM NOBA (lane 7), which com- 
pletely abolished the signal for the infectious DNA 
(compare with Fig. 1A). To rule out the possible artifact 
that the absence of SIV gag DNA may be due to incom- 
plete DNA extraction technique, we also tested for the 
ubiquitousfl-actin gene as shown in Fig. 2B, where lane 
1 shows a molecular marker (HindIII-digested q~X174 
DNA), lane 2 is thefl-actin segment amplified byfl-actin 
specific primers, and lanes 3-7 are fl-actin primer ampli- 
fication of the DNA extracted from a non-infected cell 
culture (lane 3) and infected cell cultures treated with 0 
/zM NOBA (lane 4), 0 tiM NOBA with 0.1% DMSO 
(lane 5), 10/~M NOBA (lane 6), and 20tiM NOBA (lane 
7). These results confirm that the absence of the SIV 
genome in infected cells treated with 20 pM NOBA was 
not due to the lack of extractable DNA. 
In order to identify an AZT-resistant SIV strain, vi- 
ruses from SIV-infected rhesus macaques were isolated 
and tested for their sensitivity toward AZT. The molec- 
ular clone SIVmac239 was AZT-sensitive but virus iso- 
lates from an SIVm,~239-infected rhesus macaque 
(MMU 23740) 14 months post-infection were AZT-re- 
sistant; AZT only partially inhibited the growth of SIV 
23740 compared to SIVm,c239, suggesting that the ma- 
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Fig. 2. Analysis of the cellular genome ofSIV-infected and -uninfected 
cultures by PCR. CEM x174 cells from 6-day cultures of the experi- 
ment described in Fig. 1 were used for DNA extraction. (Six-day 
cultures were used instead of 10-day cultures to ensure the presence 
of enough extractable DNA). PCR analysis was performed as de- 
scribed in section 2. For details ee section 3. 
caque virus contained a mixture of the original infecting 
virus (SIVmae239) and other, mutated viruses. A com- 
parison of the number of syncytia formed in AZT- 
treated wells revealed the complete absence of the cyto- 
pathic effect of SIV~ac239 in contrast to SIV 23740 
(Table I). 
The inhibitory action of NOBA on the replication of 
AZT-resistant SIV strains was assayed by incubating 
supernatants of 6-day-old co-cultivation systems, con- 
sisting of MMU 23740 PBMCs and CEM x174, with 
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Fig. 3. Effect of NOBA on AZT-resistant strains of SIV. Peripheral blood mononuclear cells (1.2 x 106) from an SIVmac239-infected rhesus macaque 
(MMU 23740) were co-cultivated in a 24-well tissue culture plate with 3 x 105 CEM x174 cells/ml for 6 days. Aliquots (500 ¢tl) of the co-cultivation 
supernatant were added to 3 x 105 fresh CEM x174 cells/ml. The cells were incubated at 37°C for another 2 days (until syncytia ppeared) before 
adding NOBA or AZT. Cultures were replenished with new medium containing drug on day 9. Fresh CEM x174 cells (1.75 x 105/well) and drug 
were added on day 13. (A) Virus titers in the supernatant of cultures 16 days from initial co-cultivation as determined by the SIV p27 core antigen 
capture ELISA. (B) Viability of cell cultures 16 days from initial co-cultivation as determined by the MTT assay. Data presented are the average 
of duplicate wells. 
fresh CEM x 174 cells. This system simulates conditions 
that may exist in vivo. Assays for the p27 core antigen 
Table I 
The effect of AZT on nonresistant and AZT-resistant SIVmac as as- 
sayed by syncytia formation" 
Virus AZT concentration Syncytia b 
(uM) 
SIVmac239 0 ++++ 
10 
15 
20 
25 
30 
35 
40 
SIV 23740 
(AZT-resistant) 
0 ++++ 
10 ++++ 
15 ++++ 
20 ++++ 
25 ++++ 
30 ++++ 
35 ++++ 
40 ++++ 
aCEM x174 cells (1.5 x 105/100/11) were infected with equal doses of 
SIVm,c239 or virus isolates from an SIVmac239-infected rhesus ma- 
caque (MMU 23740). Three days post-infection, AZT concentrations 
ranging from 0 to 40/.tM were added to the cells and the cultures were 
incubated for 4 days. The wells were replenished with fresh CEM 
x174 cells and AZT and incubated for an additional 3 days. Cell 
cultures were then examined for syncytia formation. 
bThe number of syncytia in cell cultures was counted in arbitrary fields 
under 60 x magnification and scored as follows: over 30 (++++), 
20~30 (+++), 10-20 (++), 1-9 (+), and 0 (-). 
with ELISA 16 days after the initial co-cultivation 
showed a NOBA dose-dependent depression of SIV 
23740 production, whereas no antiviral action of AZT 
occurred (Fig. 3A). There was no significant drug-de- 
pendent decrease of cell viability due to either NOBA 
or AZT (Fig. 3B). 
In contrast to the powerful anti-SIV action of NOBA, 
no direct effect on RT activity could be ascertained 
(Table II). 
The direct anti-SIV action of NOBA was also assayed 
with human peripheral lymphocytes that were stimu- 
lated by phytohaemagglutinin (PHA-PBL) as described 
earlier for HIV [6]. This experiment represents a direct 
comparison between SIV and HIV in the same test ys- 
tem. As seen in Fig. 4, preincubation of S lgsm m with 50 
Table II 
[3H]TTP incorporation by SIV 239-RT in the presence of NOBA" 
Concentration of NOBA (tiM) cpm (x 103) 
0 (no enzyme) 0.4 
0 761.4 
0 (0.1% DMSO) 743.8 
0.8 897.0 
8.0 836.8 
20.0 763.8 
40.0 748.8 
80.0 764.9 
400.0 690.7 
800.0 706.6 
aReverse transcriptase assays were performed with DMSO controls in 
the presence or absence of NOBA as described in section 2. 
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Fig. 4. The effect of NOBA on SIV assayed in human lymphocytes. 
A concentrated stock of SIV ....... (TCID50 =3,300) was incubated for 
30 min at 37°C with 50,uM NOBA. Afterwards, the mixture was s rial 
10-fold diluted to yield the 10 ~, 10 -2, 10 -3, 10 -4 and 10 5 dilutions. 
Each dilution was used to infect 10 6PHA-PBL for 18 h at 37°C, after 
which the free virus and drug were removed. Cells were then aliquoted 
into 96 well plates (105 cells/well with 10 replicates per dilution). 
Cultures were scored positive for infection if the r absorbance at 490
nm in the antigen capture ELISA was >3 S.D. above the mean absorb- 
ance of 10 uninfected cultures. The untreated virus cultures ([]) scored 
positive with dilutions as low as 10 -4, whereas NOBA-treated virus (m) 
did not score positive with any cultures. 
pM NOBA for 30 min at 37°C completely suppressed 
SIV replication in PHA-PBL. As determined in separate 
studies, designed to quantitate the dose-responsive ef- 
fect of NOBA on SIV replication in PBMCs, the ECs0 
value (concentration f drug that suppresses 50% virus 
replication) varied between 17 and 8 ] lM NOBA for 
SIVsm m and SIVmmbi strains, respectively. 
4. D ISCUSSION 
It is apparent (Fig. 4) that a direct action of NOBA 
on SIV is indistinguishable from its effect on HIV [6]. 
The morphologic, antigenic and molecular properties of 
SIVma c are nearly identical to those of HIV [9,15,18]. It 
is important that the retroviral zinc finger destabilizing 
action of NOBA is not confined to the zinc fingers of 
gag proteins only, but includes one of the retroviral-type 
zinc fingers of eukaryotic poly(ADP-ribose) polymerase 
[16]. Inactivation of poly(ADP-ribose) polymerase by 
zinc ejection [16] derepresses an ADP-r ibosylat ion in- 
hibited CaZ+/Mg2+-dependent donuclease in tumor 
cells and produces elective apoptosis [17]. The partici- 
pation of poly(ADP-ribose) polymerase in the regula- 
tion of DNA,  including retroviral DNA,  is being ana- 
lyzed. 
Infection of CEM x174 cells with AZT-resistant 
strains of SIV isolated from a persistently infected 
rhesus macaque has shown NOBA to be effective 
against AZT-resistant viruses. Since NOBA has a differ- 
ent molecular site of action than AZT, a synergism 
between the two drugs is predictable, as well as preven- 
tive action against he emergence of AZT-resistant viral 
mutants. The development of novel ant i -AIDS agents 
such as NOBA, which targets retroviral zinc fingers and 
does not act on reverse transcriptase, thus represents a 
new approach to AIDS chemotherapy. Combinat ion 
strategies of the mechanistically distinct AZT and 
NOBA compounds may also provide for enhanced 
chemotherapeutic efficacy, with decreased rug doses, 
lessened toxicity and a decreased likelihood for the de- 
velopment of drug-resistant variant strains. 
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